Table 1.
Correlation of clinicopathological parameters and AIB1 mRNA expression in 185 breast cancer patients
| AIB1 mRNA (n = 185) | ||||
|---|---|---|---|---|
| low | high | p-value | ||
| Age | ||||
| ≤ 50 | 59 | 39 | ||
| > 50 | 52 | 35 | 0.54 | |
| Histological type | ||||
| IDC | 107 | 66 | ||
| non-IDC | 4 | 8 | 0.05 | |
| Histological grade | ||||
| well | 41 | 15 | ||
| moderate | 47 | 41 | ||
| severe | 23 | 18 | 0.05 | |
| T stage | ||||
| T1 | 69 | 29 | ||
| T2 | 38 | 41 | ||
| T3 | 4 | 4 | 0.01 | |
| Lymph node metastasis | ||||
| negative | 59 | 46 | ||
| positive | 51 | 28 | 0.16 | |
| Stage | ||||
| T1 | 48 | 23 | ||
| T2 | 41 | 37 | ||
| T3 | 19 | 14 | ||
| T4 | 3 | 0 | 0.13 | |
| ER | ||||
| negative | 30 | 27 | ||
| positive | 81 | 47 | 0.12 | |
| PR | ||||
| negative | 31 | 27 | ||
| positive | 80 | 47 | 0.14 | |
| HER2 | ||||
| negative | 85 | 53 | ||
| positive | 26 | 21 | 2.28 | |
| AR | ||||
| negative | 19 | 5 | ||
| positive | 67 | 38 | 0.11 | |
| DAX-1 | ||||
| negative | 25 | 7 | ||
| positive | 61 | 36 | 0.08 | |
AIB1: amplified in breast cancer I; IHC: immunohistochemistry; IDC: invasive ductal carcinoma; ER: estrogen receptor; PR: progesterone receptor; and AR: androgen receptor.